LY-334370
LY-334370
LY-334370 is a selective 5-HT1F receptor agonist. It was developed by Eli Lilly and Company for the treatment of migraine.
Pronunciation
LY-334370 is pronounced as "el-why three-three-four-three-seven-zero".
Etymology
The term LY-334370 is a systematic name given by its developer, Eli Lilly and Company. The prefix LY is an abbreviation of the company's name, while the numbers 334370 are arbitrary and do not carry any specific meaning.
Pharmacology
LY-334370 is a potent and selective agonist for the 5-HT1F receptor, a subtype of the serotonin receptor. It has been shown to inhibit the release of vasoactive peptides, thus potentially reducing the inflammation and vasodilation associated with migraine.
Clinical Trials
In clinical trials, LY-334370 was found to be effective in the acute treatment of migraine. However, development was discontinued due to toxicity issues in preclinical species.
Related Terms
External links
- Medical encyclopedia article on LY-334370
- Wikipedia's article - LY-334370
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski